Phase 2bData readout

Motixafortide (BL-8040) w/ cemiplimab

Pancreatic cancer

BLRXBioLineRx

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: Motixafortide (BL-8040) w/ cemiplimab
Development stage: Phase 2b
Event type: Data readout
Indication: Pancreatic cancer

Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 2b data readout for Motixafortide (BL-8040) w/ cemiplimab in Pancreatic cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

05/27/26:- CheMo4METPANC enrollment continues. PFS interim futility analysis remains expected in 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source